ResMed Delivers Strong Q1 FY27 Results; $1 Billion Returned to Shareholders Amid Field Safety Action

ResMed (NYSE: RMD) reported a robust start to fiscal year 2027, with first‑quarter results that exceeded expectations and a record shareholder return. On October 29, for the quarter ended September 30, 2026, the company posted revenue of approximately $1.40 billion, up 6% year‑over‑year and 7% on a constant‑currency basis, while GAAP diluted earnings per share rose 23% to $2.92 and non‑GAAP EPS climbed 14% to $2.91. This performance helped fuel a significant return of capital to shareholders. These results and actions are verified from the company’s earnings release and transcript.

ResMed used proceeds from its previously announced divestiture of MatrixCare to bolster its shareholder return program. During the quarter, the company bought back approximately $936 million of its stock through open‑market and accelerated repurchases, and together with dividends, returned over $1 billion to shareholders — marking a record for the company. According to management, this reflects ResMed’s conviction in its own long‑term investment potential. These figures are substantiated by the earnings call transcript and official release.

Operationally, ResMed moved forward on several strategic fronts. The company closed the divestiture of its MatrixCare business, launched the AirTouch F40 fabric CPAP mask in the U.S., and expanded partnerships, including with Eight Sleep in the U.S. and Australia, and with NASCAR driver Tyler Reddick in an awareness initiative. Additionally, ResMed announced that Carol Burt will succeed Ron Taylor as lead independent director effective November 15, 2026. All these developments are confirmed by the company’s earnings announcement.

On the regulatory side, ResMed continues to manage its Astral Field Safety Corrective Action, including the decision to halt further sales of Astral devices while ensuring service support for existing patients. The company set aside a $42 million reserve for this effort, characterizing it as a ‘best‑in‑history’ execution of such a recall. These facts are drawn directly from the transcript.

Financial investors responded to the earnings and capital return with a flurry of analyst activity. RBC Capital maintained its Outperform rating and raised its price target to $288. KeyBanc reiterated its Overweight stance with a $277 target, Wells Fargo raised its target to $250 with Equal‑Weight, Citi lifted its target to $270 while keeping a Neutral rating, and Baird raised its target to $246 with a Neutral view. This wave of price‑target upgrades across multiple firms is reported consistently in recent analyst summaries.

Over the past week, ResMed stock experienced notable volatility. It declined approximately 8.6%, moving from about $251.48 to $229.94, with the weekly high reaching $254.99 and the low hitting $228.33. These movements and ranges are verified by weekly trading summaries.

Implications for Investors

ResMed’s strong Q1 performance demonstrates solid demand across its sleep and digital health segments, while its aggressive capital return signals confidence in future cash flow generation. The Astral Field Safety action, though operationally significant, has been financially provisioned and appears to be under control.

Analyst upgrades reinforce the positive tone, with price targets now ranging from $246 to $288. However, the stock’s recent pullback suggests some investor caution—perhaps reflecting the unchanged full‑year guidance or market digestion of the safety action impact.

Overall, the quarter sets ResMed on a favorable trajectory, and investors should monitor upcoming execution on growth initiatives, service execution of the Astral action, and any future guidance updates for signs of momentum or adjustment.